A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer

A New Drug From Sea Sponge For The Treatment Of Severe Breast Cancer.
A reborn chemotherapy treat made from a main sponge extended the lives of women with metastatic breast cancer by about 2,5 months, researchers report. The propitious finding on the drug, known as eribulin, was presented Sunday at the annual convention of the American Society of Clinical Oncology in Chicago. "We have a major need for redone therapies," noted study author Dr Christopher Twelves. "We see a statistically significant service in overall survival in a situation where we rarely see this sort of improvement".

So "Eribulin targets the mechanisms by which the cells divide, which is distinct from previous agents," explained Twelves, who is a professor of clinical cancer pharmacology and oncology and culmination of the Clinical Cancer Research Groups at the Leeds Institute of Molecular Medicine and St James' Institute of Oncology in Leeds, UK. More than 750 women were randomized to undergo either eribulin or a "treatment of physician's choice," the continue because there isn't a standard care for this type of cancer. In almost all cases, it was another chemotherapy.

The study included women who had already been treated extensively for their cancer, with the standard patient already having undergone four chemotherapies. The researchers description a 23 percent improvement in median survival when women took eribulin, with the median survival for those in the eribulin assemblage at just over 13 months vs 10,7 months in the treatment-of -choice group. "These results potentially found eribulin as a new and effective treatment for women with heavily pretreated titty cancer," said Twelves, who disclosed financial ties with Eisai, which makes eribulin.

Also featured at the congress Sunday, Italian researchers report that liver biopsies can disclose whether a breast cancer that has spread through the body has changed its cellular characteristics, such as estrogen-receptor status, progesterone-receptor prominence or HER2 status. These tumor properties often dictate the type of treatment a woman receives, import that some women may benefit from switching therapy if the characteristics of their cancer change.

In this study, 31 of 255 patients (12 percent) apophthegm their tumor status change - based on the liver biopsy results - and thus changed treatments. "We allow that when it's solid and easy to perform, a biopsy of the metastatic lesions should be considered in all patients, particularly when there has been a long lapse from first diagnosis," said study co-author Dr Giuseppe Curigliano, senior surrogate director in the division of medical oncology at the European Institute of Oncology in Milan. "The biology of the cancer may change, and that is probably to impact treatment choice".

The practice may become more common in the future. "As a complete new generation of targeted therapies come out over the next generation, it's that much more necessary to obtain tissue," said Dr Eric P Winer, a professor of nostrum at Harvard Medical School, who moderated the account conference at which the findings were released. "Not performing a biopsy should be an exception".

A third dry run presented Sunday showed that removing more than just the sentinel lymph node, the first lymph node that bust cancer spreads to, may be unnecessary. "If you look at survival, it didn't appear to force a difference whether women had their lymph nodes with cancer removed or not, and survival was quite ethical in both arms of the study," said study author Dr Armando E Giuliano, big cheese of the John Wayne Cancer Institute Breast Center in Santa Monica, Calif.

The study, however, only managed to enroll 800 patients out of 1,900 from the beginning intended, although Giuliano felt that it was "unlikely that doing in of these lymph nodes would impact survival. I think we should use this information selectively. Certainly, axillary underarm lymph node dissection for patients with micrometastases seems unwarranted. The reveal is stupefying that this operation may not be necessary".

Right now, removal of these other cancer-containing lymph nodes is common entengo. A indisputable study, from researchers at the University of Texas Southwestern Medical Center in Dallas, found that looking for heart of hearts cancer micrometastases in the sentinel node did not predict which women with mamma cancer would live longer, although finding metastases in bone marrow does seem to predict which women are going to go for a burton sooner.